News and updates on the activities, initiatives and projects involving the Fondazione Gianni Benzi Onlus.
The European Joint Programme on Rare Diseases is organizing a webinar on Real-World data, Machine learning and Deep analytics in rare diseases
XVI FTC: “Repurposing to cover unmet needs: the current scenario in Europe and the proposed changes to the pharmaceutical legislation”
Repurposing was the key topic addressed by renowned experts in the field during the XVI Foresight Training Course, organised on 18 December by Fondazione Gianni Benzi in cooperation with Università degli Studi di Bari.
EMA published the final version of the Data Quality Framework for EU medicines regulation
Expressions of interest to be considered as a candidate Data Partner for DARWIN EU® are open
A 3-day training course on “Training on strategies to foster solutions of undiagnosed rare disease cases” is being organised by Istituto Superiore di Sanità (ISS) in close collaboration with EJP RD partners. The training will be held in Rome, Italy on 13-15 March 2023.
Submission of comments on the Concept paper on the revision of the Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches is now open.
It is with great sadness we learnt of the passing of Dr Josep Torrent-Farnell on 1st December.
We are pleased to announce that Annalisa Landi has been just appointed as Steering Group member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance for term 2024-2026.
SAVE THE DATE – Meeting on Sickle Cell Disease: new challenges and perspectives in Italy (Rome, 20 November 2023)
The meeting “La Malattia Drepanocitica – nuove sfide e prospettive in Italia con le raccomandazioni della Commission di Lancet Haematology” will be held in Rome on 20 November 2023 at Sala Zuccari, Palazzo Giustiniani.
Fondazione Gianni Benzi, in collaboration with Università degli Studi di Bari Aldo Moro, organises the XVI Foresight Training Course “Repurposing to cover unmet needs: the current scenario in Europe and the proposed changes to the Pharmaceutical Legislation”.